WORKSHOP BIOMARKERS APRIL 2008

This workshop on “Biomarkers and prognosis in malignant lymphomas” is based on developments in exploring the role of a variety of biological markers related to different types of non-Hodgkin's lymphomas (follicular-, diffuse large B-cell, mantle cell- and Burkitt's lymphoma) as well as Hodgkin's lymphoma.

The final goal of this clinical research is to develop new biological prognostic indices for these major subtypes of lymphoma. In recent years, various prognostic indices, mainly based on clinical characteristics of the patient at diagnosis, have served to determine the prognostic profile and to develop prognostic factor-based treatment strategies.

However, it is now time to reconsider this based on the wealth of new biological information directly related to the lymphoma cells and the surrounding cells. In this workshop, exerts in the field will review the latest developments on molecular pathogenesis, new biomarkers and their relation to prognosis.

If you would be interested in taking part as a participant, you may register either via the ESH website or by contacting ESH marie-france.simon@univ-paris-diderot.fr . The registration fee (56OEuros) includes teaching material and meals. EHA scholarships are also available. To be eligible to apply for a scholarship, you must be an EHA Member within 15 years of graduation or have less than 10 years post-doc experience.(click here to apply for membership).

Program

Friday April 11, 2008

14:00 Opening and Welcome

Ton Hagenbeek, Amsterdam (The Netherlands)

Session I“Follicular NHL” – 14.05-16.50 hrs

Chair: Randy Gascoyne, Vancouver (Canada)

14.05-14.30 Randy Gascoyne, Vancouver (Canada)
Molecular pathogenesis of FL

14.30-14.50 James Cerhan, Rochester (U.S.A.)
The contribution of host genetics to FL prognosis

14.50-15.10 Fabrice Jardin, Rouen (France)
Cytogenetics and molecular alterations in FL

15.10-15.30 Daphne de Jong, Amsterdam (The Netherlands)
Biological prognostic factors in FL

15.30-16.00 Coffee/Tea

16.00-16.20 Daphne de Jong, Amsterdam (The Netherlands)
Predicting risk of transformation in FL

16.20-16.50 Sandra Horning, Palo Alto (U.S.A.)
Clinical implications for a new combined clinicopathological index

18.30-19.30 Drinks

19.30-22.00 Dinner

Saturday April 12, 2008

Session II “Mantle cell lymphoma” – 08.30-10.30 hrs

Chair: Martin Dreyling, Munich (Germany)

08.30-09.00 Elias Campo, Barcelona (Spain)
Molecular Pathogenesis of MCL

09.00-09.20 Evelyne Callet-Bauchu, Lyon (France)
Cytogenetic and molecular risk factors

09.20-09.40 Andreas Rosenwald, Würzburg (Germany)
RNA expression profiling

09.40-10.00 Adrian Wiestner, Bethesda (U.S.A.)
Gene Expression pattern of response to Bortezomib

10.00-10.30 Martin Dreyling, Munich (Germany)
Implications for a new prognostic index and treatment strategies

10.30–11.00 Coffee/Tea

Session III “Burkitt’s lymphoma” – 11.00-13.00 hrs

Chair: Philip Kluin, Groningen (The Netherlands)

11.00-11.20 Lorenzo Leoncini, Siena (Italy)
Diagnosis and pathogenesis of Burkitt’s lymphoma

11.20-11.40 Philip Kluin, Groningen (The Netherlands)
Burkitt's lymphoma and its mimics in adult patients

11.40-12.00 Helene Poirel, Bruxelles (Belgium)
Cytogenetics as prognostic markers in Burkitt’s lymphoma

12.00-12.30 Georg Lenz, Bethesda (U.S.A).
Gene expression and potential biomarkers / targets in Burkitt’s lymphoma

12.30-13.00 Ian Magrath, Brussels (Belgium)
What does this all mean for our treatment strategies in Burkitt’s lymphoma?

13.00-14.00Lunch

Session IV “Hodgkin’s lymphoma” – 14.00-16.00 hrs

Chair: Andreas Engert, Cologne (Germany)

14.00-14.30 Ralf Küppers, Essen (Germany)
Molecular pathogenesis of HL

14.30-14.50 Sibrand Poppema, Groningen (The Netherlands)
New molecular markers in HL

14.50-15.10 Daniel Re, Cologne (Germany)
Can SNPs predict hematotoxicity in HL? An analysis of the GHSG

15.10-15.30 Przemyslaw Juszczynski, Boston (U.S.A.)
New biomarkers and potential treatment targets in Hodgkin’s lymphoma

15.30-16.00 Andreas Engert, Cologne (Germany)
Implications of new prognostic indices for treatment

16.00-16.30 Coffee/Tea

Session V “Short oral communications” - 16.30-18.00 hrs

Chair: Anton Hagenbeek, Amsterdam (The Netherlands)

16.30-16.45 Mohit Aggarwal, Madrid (Spain)
TCL1A expression delineates biological and clinical variability in B-cell lymphoma

16.45-17.00 Ulrika Andreasson, Lund (Sweden)
Transformed diffuse large B cell lymphomas differ from follicular lymphomas in both gene and protein expression

17.00-17.15 Sharon Barrans, Leeds (United Kingdom)
A comparison of prognostic models in CHOP and CHOP-R treated DLBCL

17.15-17.30 Sylvia Hartmann, Frankfurt Am Main (Germany)
Detection of genomic imbalances in microdissected primary Hodgkin- and Reed- Sternberg cells by oligonucleotide array comparative genomic hybridization

17.30-17.45 Iwona Wlodarska, Leuven (Belgium)
Translocations targeting CCND2, CCND3 and MYCN do occur in t(11;14)-negative mantle cell lymphomas

17.45-18.00 Alexander Tzankov, Basel (Switzerland)
Rational determination of cut-off scores for prognostic biomarkers in diffuse large B-cell lymphomas

18.30-19.30 Poster viewing with cocktails

20.00-22.30 Dinner

Sunday April 13, 2008

Session VI “Diffuse large B-cell lymphoma” – 09.00-11.50 hrs

Chair: Gilles Salles, Lyon (France)

09.00-09.30Ricardo Dalla Favera, New York (U.S.A.)
Molecular Pathogenesis of DLBCL

09.30-09.50 Andreas Rosenwald, Würzburg (Germany)
What did we learn about the prognosis of DLBCL with gene profiling?

09.50-10.10 Reiner Siebert, Kiel (Germany)
Cytogenetic alterations and DLBCL prognosis ?

10.10-10.30 Randy Gascoyne, Vancouver (Canada)
Immunohistochemical markers and DLBCL prognosis

10.30-10.50 Karen Leroy, Paris (France)
Which prognostic biomarkers still remain in patients receiving immuno-chemotherapy?

10.50-11.20 Coffee/Tea

11.20-11.50 Gilles Salles, Lyon (France)
Clinical implications of biomarkers in DLBLC

11.50-12.00 Closure of the meeting Ton Hagenbeek, Amsterdam (The Netherlands)

End of the Meeting